398 related articles for article (PubMed ID: 33889528)
1. A narrative review of MET inhibitors in non-small cell lung cancer with
Santarpia M; Massafra M; Gebbia V; D'Aquino A; Garipoli C; Altavilla G; Rosell R
Transl Lung Cancer Res; 2021 Mar; 10(3):1536-1556. PubMed ID: 33889528
[TBL] [Abstract][Full Text] [Related]
2. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
3. Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?
Spagnolo CC; Ciappina G; Giovannetti E; Squeri A; Granata B; Lazzari C; Pretelli G; Pasello G; Santarpia M
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373267
[TBL] [Abstract][Full Text] [Related]
4. The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review.
Hsu R; Benjamin DJ; Nagasaka M
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509224
[TBL] [Abstract][Full Text] [Related]
5. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
Reungwetwattana T; Liang Y; Zhu V; Ou SI
Lung Cancer; 2017 Jan; 103():27-37. PubMed ID: 28024693
[TBL] [Abstract][Full Text] [Related]
6. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
7. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of
Ai X; Yu Y; Zhao J; Sheng W; Bai J; Fan Z; Liu X; Ji W; Chen R; Lu S
Ther Adv Med Oncol; 2022; 14():17588359221112474. PubMed ID: 35860830
[TBL] [Abstract][Full Text] [Related]
9. Current and future treatment options for
Hong L; Zhang J; Heymach JV; Le X
Ther Adv Med Oncol; 2021; 13():1758835921992976. PubMed ID: 33643443
[TBL] [Abstract][Full Text] [Related]
10. MET alterations in NSCLC-Current Perspectives and Future Challenges.
Remon J; Hendriks LEL; Mountzios G; García-Campelo R; Saw SPL; Uprety D; Recondo G; Villacampa G; Reck M
J Thorac Oncol; 2023 Apr; 18(4):419-435. PubMed ID: 36441095
[TBL] [Abstract][Full Text] [Related]
11. Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives.
Fraser M; Seetharamu N; Diamond M; Lee CS
Cancer Manag Res; 2023; 15():1233-1243. PubMed ID: 37941971
[TBL] [Abstract][Full Text] [Related]
12. [MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].
Yin L; Lu Y
Zhongguo Fei Ai Za Zhi; 2018 Jul; 21(7):553-559. PubMed ID: 30037377
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
[TBL] [Abstract][Full Text] [Related]
14. Capmatinib for the treatment of non-small cell lung cancer.
Vansteenkiste JF; Van De Kerkhove C; Wauters E; Van Mol P
Expert Rev Anticancer Ther; 2019 Aug; 19(8):659-671. PubMed ID: 31368815
[No Abstract] [Full Text] [Related]
15. The Treatment of a New Entity in Advanced Non-Small Cell Lung Cancer: MET exon 14 Skipping Mutation.
Rocco D; Della Gravara L; Palazzolo G; Gridelli C
Curr Med Chem; 2023 Aug; ():. PubMed ID: 37534484
[TBL] [Abstract][Full Text] [Related]
16. Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
Cortot A; Le X; Smit E; Viteri S; Kato T; Sakai H; Park K; Camidge DR; Berghoff K; Vlassak S; Paik PK
Clin Lung Cancer; 2022 May; 23(3):195-207. PubMed ID: 35272955
[TBL] [Abstract][Full Text] [Related]
17. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
18. MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review.
Dong Y; Xu J; Sun B; Wang J; Wang Z
Mol Diagn Ther; 2022 Mar; 26(2):203-227. PubMed ID: 35266116
[TBL] [Abstract][Full Text] [Related]
19. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report.
Christofyllakis K; Monteiro AR; Cetin O; Kos IA; Greystoke A; Luciani A
J Geriatr Oncol; 2022 Nov; 13(8):1071-1083. PubMed ID: 35525790
[TBL] [Abstract][Full Text] [Related]
20. MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer.
Zheng D; Wang R; Ye T; Yu S; Hu H; Shen X; Li Y; Ji H; Sun Y; Chen H
Oncotarget; 2016 Jul; 7(27):41691-41702. PubMed ID: 27223439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
